Becton, Dickinson and Company

NYSE:BDX Lagerbericht

Marktkapitalisierung: US$42.4b

Becton Dickinson Management

Management Kriterienprüfungen 4/4

Becton Dickinson CEO ist Tom Polen , ernannt in Apr 2017, hat eine Amtszeit von 9.08 Jahren. Die jährliche Gesamtvergütung beträgt $17.13M , bestehend aus 8.1% Gehalt und 91.9% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.036% der Aktien des Unternehmens, im Wert von $15.10M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.7 Jahre bzw. 7 Jahre.

Wichtige Informationen

Tom Polen

Geschäftsführender

US$17.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts8.15%
Amtszeit als Geschäftsführer9.1yrs
Eigentum des Geschäftsführers0.04%
Durchschnittliche Amtszeit des Managements3.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder7yrs

Jüngste Management Updates

Recent updates

BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook

Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.

Becton, Dickinson: Value Or Overvalued Even Now?

Apr 20

BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential

Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside

Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside

Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.

BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential

The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.

BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns

Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.

BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup

Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.

Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook

Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.

BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential

Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.

BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook

We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.

BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds

Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.

Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds

Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

Nov 09
Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

BDX Will Unlock New Growth Following Planned 2026 Business Separation

Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.

Becton, Dickinson and Company: It's Wait And See For Me

Apr 27

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Mar 30

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Tom Polen im Vergleich zu den Einnahmen von Becton Dickinson verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Dec 31 2025n/an/a

US$2b

Sep 30 2025US$17mUS$1m

US$2b

Jun 30 2025n/an/a

US$2b

Mar 31 2025n/an/a

US$1b

Dec 31 2024n/an/a

US$2b

Sep 30 2024US$17mUS$1m

US$2b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023n/an/a

US$1b

Sep 30 2023US$17mUS$1m

US$1b

Jun 30 2023n/an/a

US$2b

Mar 31 2023n/an/a

US$2b

Dec 31 2022n/an/a

US$1b

Sep 30 2022US$17mUS$1m

US$2b

Jun 30 2022n/an/a

US$1b

Mar 31 2022n/an/a

US$1b

Dec 31 2021n/an/a

US$1b

Sep 30 2021US$14mUS$1m

US$2b

Jun 30 2021n/an/a

US$1b

Mar 31 2021n/an/a

US$1b

Dec 31 2020n/an/a

US$2b

Sep 30 2020US$12mUS$952k

US$245m

Jun 30 2020n/an/a

US$786m

Mar 31 2020n/an/a

US$923m

Dec 31 2019n/an/a

US$760m

Sep 30 2019US$6mUS$900k

US$1b

Vergütung im Vergleich zum Markt: TomDie Gesamtvergütung ($USD17.13M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD14.54M).

Entschädigung vs. Einkommen: TomDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Tom Polen (52 yo)

9.1yrs
Amtszeit
US$17,129,139
Vergütung

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen served as an Independent Director at Walgreens...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Polen
President9.1yrsUS$17.13m0.036%
$ 15.1m
Michael Garrison
Executive VP & President of Medical Segment and BioPharma Systems Segments3.7yrsUS$3.65m0.0043%
$ 1.8m
Richard Byrd
Executive VP & President of Interventional Segment3.7yrsUS$3.40m0.0011%
$ 488.0k
Michael Feld
Executive VP & Chief Revenue Officerless than a yearUS$4.10m0.0074%
$ 3.2m
Vitor Roque
Senior VP of Business Finance & Interim CFOless than a yearkeine Daten0.0023%
$ 971.8k
Pamela Spikner
Senior VP1.3yrskeine Daten0.0012%
$ 496.5k
Elizabeth McCombs
Executive VP & CTO5.1yrskeine Datenkeine Daten
Joseph Smith
Senior VP & Chief Scientific Officer4.5yrskeine Datenkeine Daten
Denise Fleming
Executive VP of Technology & Global Services and Chief Information Officer4.3yrskeine Datenkeine Daten
Shawn Bevec
Senior Vice President of Investor Relationsless than a yearkeine Datenkeine Daten
Claudia Curtis
Senior VPno datakeine Datenkeine Daten
Lanesha Minnix
Executive VP & General Counselless than a yearkeine Datenkeine Daten
3.7yrs
Durchschnittliche Betriebszugehörigkeit
49yo
Durchschnittliches Alter

Erfahrenes Management: BDXDas Führungsteam des Unternehmens gilt als erfahren (3.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Polen
President6.3yrsUS$17.13m0.036%
$ 15.1m
Robert Eckert
Lead Independent Director9.7yrsUS$365.17k0.0037%
$ 1.6m
Timothy Ring
Independent Director9.3yrsUS$335.17k0.022%
$ 9.2m
Jeffrey Henderson
Independent Director7.8yrsUS$360.17k0.0032%
$ 1.4m
Christopher Ian Jones
Independent Director15.8yrsUS$365.17k0.0085%
$ 3.6m
Bertram Scott
Independent Director23.7yrsUS$375.17k0.013%
$ 5.5m
Gregory Hayes
Independent Director1.2yrsUS$223.45k0.0019%
$ 785.1k
Catherine Burzik
Independent Director13.3yrsUS$360.17k0.0033%
$ 1.4m
William Brown
Independent Director4.3yrsUS$335.17k0.0016%
$ 696.0k
Robert Huffines
Independent Directorless than a yearkeine Daten0%
$ 0
Carrie Byington
Independent Director4.6yrsUS$345.17k0.0018%
$ 746.9k
Joanne Waldstreicher
Independent Director2.8yrsUS$336.17k0.00048%
$ 203.7k
7.0yrs
Durchschnittliche Betriebszugehörigkeit
63.5yo
Durchschnittliches Alter

Erfahrener Vorstand: BDXDie Vorstandsmitglieder gelten als erfahren (7 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/01 10:20
Aktienkurs zum Tagesende2026/05/01 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/09/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Becton, Dickinson and Company wird von 35 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays